Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Thrombocytopenia during heparin therapy: a clinical conundrum

Nature Clinical Practice Cardiovascular Medicine volume 5, pages 440–441 (2008)Cite this article

boxed-textOliveira GB et al. for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators (2008) Incidence and prognostic significance of thrombocytopenia in patient treated with prolonged heparin therapy. Arch Intern Med 168: 94–102

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Warkentin TE et al. (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108: 2937–2941

    Article  CAS  Google Scholar 

  2. Greinacher A et al. (2007) Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5: 1666–1673

    Article  CAS  Google Scholar 

  3. Lo GK et al. (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4: 759–765

    Article  CAS  Google Scholar 

  4. Greinacher A et al. (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost 94: 132–135

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. The Zena and Michael A Wiener Cardiovascular Institute and The Marie Josée and Henry R Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029, USA jonathan.halperin@mssm.edu

Authors and Affiliations

  1. JL Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at the Mount Sinai School of Medicine, and Director of Clinical Cardiology Services in the Zena and Michael A Wiener Cardiovascular Institute at Mount Sinai Medical Center, New York, NY, USA.,

    Jonathan L Halperin

Authors
  1. Jonathan L Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

JL Halperin has received consultancy fees from Astellas Pharma, Bayer Healthcare, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Johnson & Johnson and Sanofi-Aventis for advisory activities involving the development of new anticoagulant drugs, none of which are currently approved for clinical use in any indication.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Halperin, J. Thrombocytopenia during heparin therapy: a clinical conundrum. Nat Rev Cardiol 5, 440–441 (2008). https://doi.org/10.1038/ncpcardio1254

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1254

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing